Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Sumitomo Pharma Co., Ltd.

https://www.sumitomo-pharma.com/

Latest From Sumitomo Pharma Co., Ltd.

Five Recent Deals Show ADCs Aren’t Cooling Off For Summer

Bookmark
  • Analysis
By Joseph Haas

While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.

Deals Business Strategies

Emerging Modalities Stand Out In Recovering Korean Deal Market

Bookmark
  • Analysis
By Jung Won Shin

While Korean biopharma companies’ out-licensing deals have remained lackluster in the past couple of years, activity around emerging modalities, led by ADCs, have been increasing in line with global trends.

South Korea Research & Development

Finance Watch: Actuate Launches 15th Biopharma IPO In The US For 2024

Bookmark
  • Analysis
By Mandy Jackson

Public Company Edition: Actuate Therapeutics grossed $22.4m in its first-time offering, while already-public companies recently tapped a variety of sources for funding. Arrowhead negotiated a credit facility for up to $500m and ANI sold $275m worth of notes, among other financings.

Financing Business Strategies

Korean Biopharma Financings Remain In Doldrums But Recovery In Sight?

Bookmark
  • Analysis
By Jung Won Shin

As investor sentiment around Korean biopharma IPOs and financings remained tepid in the second quarter, companies turned to other ways of raising money, including rights offerings. But there are signs of recovery and upcoming catalysts, while on the M&A front Boryung divested a vaccine subsidiary to a private equity consortium. 

South Korea Companies
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Adagio Pharmaceuticals Ltd.
    • Altavant Sciences
    • Boston Biomedical, Inc.
    • Boston Biomedical Pharma, Inc.
    • Cannasat Therapeutics Inc.
    • Cynapsus Therapeutics, Inc.
    • Dainippon Sumitomo Pharma Co., Ltd.
    • Dainippon Sumitomo Pharma Europe Ltd.
    • DS Pharma Promo Co., Ltd,
    • Elevation Pharmaceuticals, Inc.
    • Enzyvant Therapeutics, Inc.
    • Enzyvant Sciences, Ltd.
    • Myovant Sciences Ltd
    • Myovant Sciences GmbH
    • Myovant Sciences, Inc.
    • Oryx Pharmaceuticals Inc.
    • SB Bioscience Co., Ltd.
    • Spirovant Sciences
    • Sumitomo Chemical Co., Ltd.
    • Sumitomo Dainippon Pharma America, Inc. (formerly Dainippon Sumitomo Pharma America Holdings, Inc.)
    • Sumitomo Dainippon Pharma Oncology, Inc.
    • Sumitomo Pharmaceuticals America
    • Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
    • Sumitovant Biopharma
    • Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.)
    • Sunovion Pharmaceuticals Europe Ltd.
    • Sunovion Respiratory Development Inc.
    • Tolero Pharmaceuticals, Inc.
    • Urovant Sciences, Inc.
    • Sumitomo Pharmaceuticals Taiwan Co., Ltd.
    • Sumitomo Dainippon Pharma Co., Ltd.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By